Participants will only be counted (1) once at the preferred term (PT) level, (2) once at the system organ class (SOC) level, and (3) once in the ‘Total participant’ row at their worst CTC grade, regardless of SOC or PT. Laboratory abnormalities Laboratory values will be graded according to CTCAE v4.0327.Laboratory shift table using the worst CTC grade on treatment per participant Abbreviations: AE = adverse event; CTC = common terminology cr iteria; CTCAE = common terminology criteria for adverse events; DLT = dose-limiting toxicity; PT = pre ferred term; SAE = serious adverse event; SOC = system organ class. 10.3.3 Pharmacokinetic Analyses The PK parameters to be assessed, if data permit, include: Cmax Maximum observed plasma concentration Tmax Time of maximum observed plasma concentr ation AUC(0-T) Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration AUC(TAU) Area under the concentration-time curve in 1 dosing interval The PK parameters that may be assessed, if data permit and if deemed necessary, include: Cmin The minimum observed concentration within a dosing interval (eg, occurring no matter when over the dosing interval) CLT Total body clearance Css-avg Average concentration over a dosing interval (AUC[TAU]/tau) AI Accumulation index; ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC[TAU], Cmax, and concentrations at the end of dosing interval (Ctau). T-HALF Apparent terminal half-life in serum T-HALFeff Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC[TAU], Cmax, and Ctau) Revised Protocol No.: 04 Date: 31-May-2019 150 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS The following PK parameter will be reported as a separate listing, summary, and plot: •Ctrough: Trough observed plasma concentrations (this includes pre-dose concentrations and Ctau) Individual participant PK parameter values w ill be derived by noncompartmental methods by a validated PK analysis program. Actual times will be used for the analyses. Endpoint Statistical Analysis Methods Cmax, AUC(0-T), AUC(TAU), Ctau, CLT, Css-avg, AI_AUC, AI_Cmax, AI-Ctau, THALFeff_AUC, THALFeff_CmaxSummary statistics: geometric means and coefficients of variation Tmax Summary statistics: medians and ranges Ctrough Summary statistics to assess attainment of steady state: geometric means and coefficients of variation; plots vs time by dose Revised Protocol No.: 04 Date: 31-May-2019 151 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS 10.3.4 Immunogenicity Analyses Endpoint Statistical Analysis Methods Incidence of ADA to BMS-986226 Baseline ADA-positive participant is defined as a participant who has an ADA-detected sample at baselinea. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatmentFrequency distribution of baseline ADA-positive participants and ADA-positive participants after initiation of the treatment aBaseline sample is the last sample before initiation of the treatment. Abbreviations: ADA = anti-drug antibody.